Table 2.
Results of the randomized clinical trials using SLT
| Author, year | SLT IOP red (mmHg) at 6 m—1 y (months) | SLT IOP red (mmHg) end of study (months) | Control group IOP red (mmHg) at 6 m—1 y (months) | Control group IOP red (mmHg) end of study (months) | SLT definition of success | SLT success rate at 6 m—1 y (%) (months) | SLT success rate at end of study (%) (months) |
|---|---|---|---|---|---|---|---|
| Lai, 2004 [22] | 8.0 (12) | 8.6 ± 6.7 (60) | 7.0 (12) | 8.7 ± 6.6 (60) | IOP < 21 mmHg | 97 | 72.41 (60) |
| Nagar, 2005 [23] | NA | -- | NA | -- | >20 % IOP red | 90° = 34 | -- |
| 180° = 65 | |||||||
| 360° = 82 (10) | |||||||
| Nagar, 2009 [24] | 6.2 ± 0.8 (4–6) | -- | 7.8 ± 0.8 (4–6) | -- | >20 % IOP red | 75 (4–6) | -- |
| Katz, 2012 [21] | 6.3 ± 2.7 (12) | -- | 7.0 ± 1.8 (12) | -- | IOP ≤ 2 mmHg above target IOP + no VF loss ≥ 3 unit | 80 (12) | -- |
| Bovell, 2011 [26] | 6.0 ± 6.1 (12) | 7.4 ± 7.3 (60) | 6.0 ± 4.8 (12) | 6.7 ± 6.6 (60) | >20 % IOP red | 71 (12) | 25 (60) |
| Liu, 2012 [27] | 3.8 (12) | 1.8 (24) | 2.7 (12) | 2.8 (24)a | def 1: > 20 % IOP red | 55 (12) | def 1: 40 (24)a |
| def 2: IOP < target IOP | def 2: 75 (24)a | ||||||
| Rosenfeld, 2012 [28] | 4.3 (12) | -- | 3.23 (12) | -- | ≥15 % IOP red | 75 (12) | -- |
| Kent, 2013 [29] | 6.8 (6) | -- | 7.0 (6) | -- | >20 % IOP red | 73 (6) | -- |
Abbreviations: IOP red = IOP reduction; m = months; y = year; NA = not available; red = reduction; VF = visual field; def = definition; end of study = when study was longer than 12 months
aResults of Liu et al. [27] at end of study (37 months) were not available